Hexagon Bio raises $62M Series A+ led by CEO.

<div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <p>Hexagon Bio raises $62M Series A+ led by CEO.</p><p>Hexagon Bio develops providing new payload mechanisms for antibody-drug conjugates (ADCs).</p><p>Hexagon Bio is based in Menlo Park.</p><p>The company is led by CEO Maureen Hillenmeyer.</p><table class="vc-deal-terms"><tbody><tr><th>Company</th><td>Hexagon Bio</td></tr><tr><th>Round</th><td>Series A+</td></tr><tr><th>Amount</th><td>$62M</td></tr><tr><th>Lead Investor</th><td>CEO</td></tr><tr><th>Founders</th><td>Maureen Hillenmeyer</td></tr><tr><th>Sectors</th><td>biopharmaceutical</td></tr></tbody></table>
</div>
</div>
</div>


<div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <p>Hexagon Bio raises <strong>$62M</strong> Series A+ led by CEO.</p>
<p>Hexagon Bio develops providing new payload mechanisms for antibody-drug conjugates (ADCs).</p>
<p>Hexagon Bio is based in Menlo Park.</p>
<p>The company is led by CEO Maureen Hillenmeyer.</p>
<table class="vc-deal-terms"><tbody>
<tr>
<th>Company</th>
<td>Hexagon Bio</td>
</tr>
<tr>
<th>Round</th>
<td>Series A+</td>
</tr>
<tr>
<th>Amount</th>
<td><strong>$62M</strong></td>
</tr>
<tr>
<th>Lead Investor</th>
<td>CEO</td>
</tr>
<tr>
<th>Founders</th>
<td>Maureen Hillenmeyer</td>
</tr>
<tr>
<th>Sectors</th>
<td>biopharmaceutical</td>
</tr>
</tbody></table>
</div>
</div>
</div>


Hexagon Bio Raises $62M From Ceo

Hexagon Bio Raises $62M From Ceo | Traded VC

ABOUT THIS STORY

<div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <p>Hexagon Bio raises <strong>$62M</strong> Series A+ led by CEO.</p>
<p>Hexagon Bio develops providing new payload mechanisms for antibody-drug conjugates (ADCs).</p>
<p>Hexagon Bio is based in Menlo Park.</p>
<p>The company is led by CEO Maureen Hillenmeyer.</p>
<table class="vc-deal-terms"><tbody>
<tr>
<th>Company</th>
<td>Hexagon Bio</td>
</tr>
<tr>
<th>Round</th>
<td>Series A+</td>
</tr>
<tr>
<th>Amount</th>
<td><strong>$62M</strong></td>
</tr>
<tr>
<th>Lead Investor</th>
<td>CEO</td>
</tr>
<tr>
<th>Founders</th>
<td>Maureen Hillenmeyer</td>
</tr>
<tr>
<th>Sectors</th>
<td>biopharmaceutical</td>
</tr>
</tbody></table>
</div>
</div>
</div>

Hexagon Bio Raises $62M From Ceo

ABOUT THIS STORY

Modern Intelligence Raises $5M Seed Led by Bedrock Capital

Project Omega Raises $80M From Founder

Spines Raises $64M

Company	Hexagon Bio
Round	Series A+
Amount	$62M
Lead Investor	CEO
Founders	Maureen Hillenmeyer
Sectors	biopharmaceutical

Hexagon Bio Raises $62M From Ceo

ABOUT THIS STORY

More articles

Modern Intelligence Raises $5M Seed Led by Bedrock Capital

Project Omega Raises $80M From Founder

Spines Raises $64M